Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q6ZSU1

UPID:
C2G1P_HUMAN

ALTERNATIVE NAMES:
Cytochrome P450 2G1 pseudogene

ALTERNATIVE UPACC:
Q6ZSU1

BACKGROUND:
Cytochrome P450 2G1 pseudogene, or Putative inactive cytochrome P450 2G1, is part of the extensive cytochrome P450 enzyme family, known for their essential role in the metabolism of drugs and toxins. This pseudogene variant highlights the genetic diversity and potential for regulatory mechanisms within this crucial enzyme family.

THERAPEUTIC SIGNIFICANCE:
Exploring the function and regulatory mechanisms of Putative inactive cytochrome P450 2G1 offers a promising avenue for drug discovery and development. By delving into its relationship with the broader cytochrome P450 family, researchers can uncover new therapeutic targets and strategies for treating a wide range of diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.